Meeting
2021 ASCO Annual Meeting
NCT04552223: A phase II study of nivolumab plus BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094).
Authors
Jose Lutzky
University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
Jose Lutzky , Lynn G. Feun , Norma Magallanes , Deukwoo Kwon , J. William Harbour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04552223
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9590)
DOI
10.1200/JCO.2021.39.15_suppl.TPS9590
Abstract #
TPS9590
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II study of anti-PD1 monoclonal antibody (Nivolumab) administered in combination with anti-LAG3 monoclonal antibody (Relatlimab) in patients with metastatic melanoma naive to prior immunotherapy in the metastatic setting.
First Author: Anjali Rohatgi
Poster
2019 ASCO Annual Meeting
A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).
First Author: Aparna Raj Parikh
Poster
2022 ASCO Annual Meeting
Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy.
First Author: Florent Peyraud
Poster
2017 ASCO Annual Meeting
Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.
First Author: Paolo Antonio Ascierto